Merck taps Evidation to use apps, wearables to detect early stages of Alzheimer’s
Merck has tapped McKesson Ventures portfolio company Evidation Health to explore whether data collected from wearables and smartphone apps can help to detect Alzheimer’s disease before visible changes in cognition take place. The companies are partnering to research whether sensor data can be used to develop digital measures to accelerate drug development for Alzheimer’s. The work builds on Evidation’s previous research on neurodegenerative disease detection from digital sensors and apps. “We know that digital measures have the potential to make visible what is currently clinically invisible. This...